2017 Parkinson Study Group Symposium and Training

2017年帕金森研究组研讨会及培训

• 批准号: 9398499
• 负责人: MICHAEL A SCHWARZSCHILD
• 金额: $ 2.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9398499
• 关键词: Advocate; Alzheimer' s Disease; Ataxia; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Dystonia; Education; Educational Activities; Educational workshop; Ensure; Etiology; Fostering; Foundations; Future; Gilles de la Tourette syndrome; Goals; Huntington Disease; Immunotherapeutic agent; Immunotherapy; Investments; Knowledge; Learning; Mentors; Modification; Movement Disorders; Neurobiology; Neurodegenerative Disorders; Neurology; Parkinson Disease; Pathogenesis; Patient Care; Patients; Peer Review; Pharmacology; Program Reviews; Research; Research Activity; Research Methodology; Research Personnel; Research Project Grants; Research Proposals; Scientist; Therapeutic; Training; Training and Education; Translational Research; Tremor; career; career development; design; drug development; experience; genetic epidemiology; improved; insight; meetings; mobile computing; nervous system disorder; neuroimaging; novel; novel therapeutics; patient oriented; posters; programs; research study; skills; symposium; tool

Abstract The proposed conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present the “31st Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Monday, September 17, 2017 in Fort Myers, FL. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposium will focus on the emergence of immuno-therapy as a promising strategy for disease modification in Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, drug development, regulatory and patient perspectives. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Disease Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator workshop on novel research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and studies in clinical neurology.

抽象的 拟议的会议项目集中在年度临床研究研讨会上 帕金森研究小组（PSG）和相关的年会活动将促进 早期研究人员的教育和培训，以确保最高质量的翻译 并且继续进行临床研究，以改善帕金森氏症的治疗和 相关神经疾病。这个项目目标将通过两个特定目标（SAS）实现。 在SA＃1中，PSG将介绍“关于病因，发病机理和 治疗帕金森氏病和其他运动障碍” 亨廷顿研究小组（HSG），肌张力障碍研究小组（DSG），图雷特综合征研究小组 （TSSG），合作社（CAG）和震颤研究小组（TRG），星期一， 2017年9月17日在佛罗里达州迈尔斯堡。同行评审的程序包括平台和 海报演示以现场格式，观众参与。研讨会将重点放在 免疫治疗的出现是作为疾病改变的承诺策略 帕金森氏和其他神经退行性疾病，主题演讲传达 完全神经生物学，药物开发，监管和患者观点。 SA＃2 旨在为早期临床研究人员提供运动障碍训练 PD临床研究的多方面实践取向。选定的初级调查人员将 除了 研讨会，包括a）与经验丰富的患者倡导者的直接交流 疾病基金会的一对（帕金森研究的倡导者）计划，以了解患者如何 投入可以使他们的研究受益，b）PSG指导委员会的初级调查员 新研究方法的研讨会。完成参与的初级调查员 项目将做好更好的准备和动力，以追求和研究 临床神经病学。